Ratings for Kymera Therapeutics (NASDAQ:KYMR) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Kymera Therapeutics, presenting an average target of $48.6, a high estimate of $53.00, and a low estimate of $46.00. Witnessing a positive shift, the current average has risen by 1.78% from the previous average price target of $47.75.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions...
Login or create a forever free account to read this news
Sign up/Log in